STEVEN D DAVELUY
- Type
- Physician · Allopathic & Osteopathic Physicians / Dermatology
- Where
- DEARBORN, MI
- NPI
- 1467611475
- Received
- $350,791 in 803 records, 2019 to 2025 ($350,078 general, $713 research)
- As principal investigator
- $338,800 of research payments to others in 102 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 221 | $120,741 |
| 2025 | Research payment | 1 | $713 |
| 2024 | General payment | 186 | $106,215 |
| 2023 | General payment | 130 | $37,029 |
| 2022 | General payment | 93 | $27,677 |
| 2021 | General payment | 73 | $7,420 |
| 2020 | General payment | 33 | $5,509 |
| 2019 | General payment | 66 | $45,486 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 76 | $166,975 |
| Consulting Fee | 42 | $130,409 |
| Travel and Lodging | 103 | $31,639 |
| Food and Beverage | 575 | $20,828 |
| Research payment | 1 | $713 |
| Education | 6 | $225 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-26 | UCB, Inc. | $2,075 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-22 | Novartis Pharmaceuticals Corporation | $2,200 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-19 | Novartis Pharmaceuticals Corporation | $3,300 | Consulting Fee | Cash or cash equivalent | COSENTYX Drug, Dermatology | 2025 | |
| 2025-12-19 | SANOFI US SERVICES INC. | $41 | Consulting Fee | Cash or cash equivalent | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-12-18 | KYOWA KIRIN, INC. | $800 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-18 | UCB, Inc. | $153 | Travel and Lodging | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-18 | UCB, Inc. | $88 | Travel and Lodging | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-18 | UCB, Inc. | $64 | Travel and Lodging | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-18 | UCB, Inc. | $36 | Travel and Lodging | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-16 | Krystal Biotech Inc | $16 | Food and Beverage | In-kind items and services | VYJUVEK Drug, DERMATOLOGY | 2025 | |
| 2025-12-12 | UCB, Inc. | $7,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-12 | LEO Pharma Inc. | $22 | Food and Beverage | In-kind items and services | SPEVIGO Biological, DERMATOLOGY | 2025 | |
| 2025-12-11 | Incyte Corporation | $4,500 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-05 | Takeda Pharmaceuticals U.S.A., Inc. | $789 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-12-05 | Takeda Pharmaceuticals U.S.A., Inc. | $96 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-12-05 | Takeda Pharmaceuticals U.S.A., Inc. | $94 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-12-05 | Takeda Pharmaceuticals U.S.A., Inc. | $14 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-05 | Takeda Pharmaceuticals U.S.A., Inc. | $14 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-05 | Takeda Pharmaceuticals U.S.A., Inc. | $8 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-04 | Takeda Pharmaceuticals U.S.A., Inc. | $219 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-12-04 | Takeda Pharmaceuticals U.S.A., Inc. | $121 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-12-04 | Regeneron Healthcare Solutions, Inc. | $21 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-12-01 | ABBVIE INC. | $4,025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-01 | PFIZER INC. | $13 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-11-23 | UCB SA | $20 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-22 | UCB SA | $668 | Travel and Lodging | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-22 | UCB SA | $659 | Travel and Lodging | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-22 | UCB SA | $330 | Travel and Lodging | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-22 | UCB SA | $38 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-22 | UCB SA | $34 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-22 | UCB SA | $26 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-21 | SANOFI US SERVICES INC. | $2,460 | Consulting Fee | Cash or cash equivalent | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-11-21 | UCB SA | $65 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-21 | SUN PHARMACEUTICAL INDUSTRIES INC. | $14 | Food and Beverage | In-kind items and services | Leqselvi Biological, Dermatology | 2025 | |
| 2025-11-20 | UCB, Inc. | $3,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-20 | UCB, Inc. | $2,075 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-20 | UCB, Inc. | $2,075 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-20 | ABBVIE INC. | $1,725 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-19 | UCB, Inc. | $115 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-19 | UCB, Inc. | $17 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-18 | Incyte Corporation | $1,250 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-18 | UCB, Inc. | $667 | Travel and Lodging | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-18 | UCB, Inc. | $641 | Travel and Lodging | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-18 | Novartis Pharmaceuticals Corporation | $27 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-11-13 | UCB, Inc. | $75 | Travel and Lodging | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-12 | UCB, Inc. | $83 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-11 | SANOFI US SERVICES INC. | $96 | Food and Beverage | In-kind items and services | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-11-11 | UCB, Inc. | $40 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-07 | ABBVIE INC. | $764 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-07 | ABBVIE INC. | $175 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-07 | ABBVIE INC. | $42 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-06 | UCB, Inc. | $2,075 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-06 | UCB, Inc. | $2,075 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-06 | GENZYME CORPORATION | $24 | Food and Beverage | In-kind items and services | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-11-04 | Galderma Laboratories, L.P. | $37 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-04 | SUN PHARMACEUTICAL INDUSTRIES INC. | $22 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-11-02 | UCB, Inc. | $33 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-02 | UCB, Inc. | $25 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-02 | Incyte Corporation | $17 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-11-01 | Incyte Corporation | $132 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-11-01 | Novartis Pharmaceuticals Corporation | $36 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-11-01 | Galderma Laboratories, L.P. | $13 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-10-31 | ABBVIE INC. | $1,725 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-31 | Incyte Corporation | $25 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-10-29 | Novartis Pharmaceuticals Corporation | $3,000 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-24 | Novartis Pharmaceuticals Corporation | $19 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-10-24 | Novartis Pharmaceuticals Corporation | $2 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-10-23 | Merck Sharp & Dohme LLC | $30 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-10-23 | Acera Surgical, Inc. | $22 | Food and Beverage | In-kind items and services | Restrata Wound Matrix Device, Wound Care | 2025 | |
| 2025-10-16 | Novartis Pharmaceuticals Corporation | $6 | Food and Beverage | In-kind items and services | ILARIS Drug, Immunology | 2025 | |
| 2025-10-14 | UCB, Inc. | $36 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-10-14 | Janssen Biotech, Inc. | $33 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-10-08 | UCB, Inc. | $42 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-10-07 | SUN PHARMACEUTICAL INDUSTRIES INC. | $15 | Food and Beverage | In-kind items and services | Leqselvi Biological, Dermatology | 2025 | |
| 2025-10-07 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-02 | Incyte Corporation | $3,000 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-29 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-09-24 | Organogenesis Inc. | $34 | Food and Beverage | In-kind items and services | PURAPLY WOUND MATRIX Device, WOUND CARE | 2025 | |
| 2025-09-23 | Krystal Biotech Inc | $8 | Food and Beverage | In-kind items and services | VYJUVEK Drug, DERMATOLOGY | 2025 | |
| 2025-09-23 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-09-19 | Novartis Pharmaceuticals Corporation | $34 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-09-18 | Incyte Corporation | $94 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-09-18 | Incyte Corporation | $16 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-09-18 | Incyte Corporation | $10 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-09-16 | Krystal Biotech Inc | $24 | Food and Beverage | In-kind items and services | VYJUVEK Drug, DERMATOLOGY | 2025 | |
| 2025-09-13 | Almirall LLC | $32 | Food and Beverage | In-kind items and services | Seysara Drug, Dermatology | 2025 | |
| 2025-09-10 | Novartis Pharmaceuticals Corporation | $713 | Research payment | In-kind items and services | COSENTYX Drug, Dermatology | Research Publication/ Writing Support | 2025 |
| 2025-09-10 | UCB, Inc. | $59 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-09-06 | GENZYME CORPORATION | $7,983 | Consulting Fee | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-06 | GENZYME CORPORATION | $215 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-06 | GENZYME CORPORATION | $200 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-06 | GENZYME CORPORATION | $115 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-06 | GENZYME CORPORATION | $64 | Travel and Lodging | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-05 | LEO Pharma Inc. | $22 | Food and Beverage | In-kind items and services | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-09-03 | ABBVIE INC. | $26 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-03 | Helsinn Therapeutics (U.S.), Inc. | $22 | Food and Beverage | In-kind items and services | VALCHLOR Drug, ONCOLOGY | 2025 | |
| 2025-09-02 | Incyte Corporation | $6,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-08-29 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-08-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,210 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SPEVIGO Drug, IMMUNOLOGY | 2025 | |
| 2025-08-26 | UCB, Inc. | $38 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-08-26 | ABBVIE INC. | $1 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-08-19 | UCB, Inc. | $10,800 | Consulting Fee | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,402 | Consulting Fee | Cash or cash equivalent | SPEVIGO Drug, IMMUNOLOGY | 2025 | |
| 2025-08-19 | UCB, Inc. | $64 | Travel and Lodging | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-08-19 | KYOWA KIRIN, INC. | $23 | Food and Beverage | In-kind items and services | POTELIGEO Drug, MONOCLONAL ANTIBODY | 2025 | |
| 2025-08-13 | Arcutis Biotherapeutics, Inc. | $20 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-08-12 | Incyte Corporation | $821 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-08-12 | Incyte Corporation | $251 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-08-12 | Incyte Corporation | $76 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-08-12 | Incyte Corporation | $64 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-08-05 | Incyte Corporation | $1,250 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-08-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | $103 | Food and Beverage | In-kind items and services | SPEVIGO Drug, IMMUNOLOGY | 2025 | |
| 2025-08-05 | UCB, Inc. | $33 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-08-02 | UCB, Inc. | $30 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-08-02 | UCB, Inc. | $26 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-08-02 | UCB, Inc. | $10 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-08-02 | UCB, Inc. | $9 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-08-02 | UCB, Inc. | $7 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-08-01 | UCB, Inc. | $398 | Travel and Lodging | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-08-01 | UCB, Inc. | $257 | Travel and Lodging | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-08-01 | UCB, Inc. | $211 | Travel and Lodging | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-08-01 | UCB, Inc. | $125 | Travel and Lodging | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-08-01 | UCB, Inc. | $65 | Travel and Lodging | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-07-22 | Amgen Inc. | $13 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-07-20 | GENZYME CORPORATION | $19 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-17 | UCB, Inc. | $32 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-07-17 | PFIZER INC. | $21 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-07-12 | Incyte Corporation | $46 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-07-11 | UCB, Inc. | $27 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-07-10 | GENZYME CORPORATION | $113 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-07-09 | Helsinn Therapeutics (U.S.), Inc. | $19 | Food and Beverage | In-kind items and services | VALCHLOR Drug, ONCOLOGY | 2025 | |
| 2025-07-08 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-07-08 | Novartis Pharmaceuticals Corporation | $0 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-07-03 | UCB, Inc. | $2,075 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-07-03 | UCB, Inc. | $2,075 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-07-02 | Chiesi USA, Inc. | $17 | Food and Beverage | Cash or cash equivalent | FILSUVEZ Drug, DERMATOLOGY | 2025 | |
| 2025-06-26 | Insmed, Inc. | $581 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-06-26 | Insmed, Inc. | $237 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-06-26 | Insmed, Inc. | $115 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-06-26 | Insmed, Inc. | $74 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-26 | Insmed, Inc. | $64 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-06-26 | Insmed, Inc. | $51 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-26 | Insmed, Inc. | $29 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-26 | Insmed, Inc. | $29 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-25 | ABBVIE INC. | $2,875 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-06-13 | Novartis Pharmaceuticals Corporation | $27 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-06-11 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $100 | Food and Beverage | In-kind items and services | Cabtreo Drug, Dermatology | 2025 | |
| 2025-06-10 | Janssen Biotech, Inc. | $21 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-06-03 | ABBVIE INC. | $133 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-06-03 | Regeneron Healthcare Solutions, Inc. | $23 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-05-29 | UCB, Inc. | $119 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-29 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-05-29 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-05-27 | Janssen Biotech, Inc. | $19 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-05-25 | Regeneron Healthcare Solutions, Inc. | $24 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-05-23 | GENZYME CORPORATION | $7 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-05-22 | KYOWA KIRIN, INC. | $26 | Food and Beverage | In-kind items and services | POTELIGEO Drug, MONOCLONAL ANTIBODY | 2025 | |
| 2025-05-15 | UCB, Inc. | $2,075 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-05-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | $29 | Food and Beverage | In-kind items and services | SPEVIGO Drug, IMMUNOLOGY | 2025 | |
| 2025-05-13 | UCB, Inc. | $39 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-05-13 | Regeneron Healthcare Solutions, Inc. | $34 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-05-08 | GENZYME CORPORATION | $137 | Food and Beverage | In-kind items and services | WAYRILZ Drug, Immunology | 2025 | |
| 2025-04-29 | UCB, Inc. | $22 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-04-18 | LEO Pharma Inc. | $15 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-04-17 | Novartis Pharmaceuticals Corporation | $34 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-04-14 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-04-11 | UCB, Inc. | $38 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-04-10 | UCB, Inc. | $64 | Travel and Lodging | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-04-09 | Regeneron Pharmaceuticals, Inc. | $30 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-04-03 | KYOWA KIRIN, INC. | $20 | Food and Beverage | In-kind items and services | POTELIGEO Drug, MONOCLONAL ANTIBODY | 2025 | |
| 2025-04-02 | UCB, Inc. | $17 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-03-28 | LEO Pharma Inc. | $20 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-03-26 | Biofrontera Inc. | $30 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-20 | Novartis Pharmaceuticals Corporation | $3,000 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-03-20 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | ILARIS Drug, Immunology | 2025 | |
| 2025-03-19 | ABBVIE INC. | $32 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-03-18 | Helsinn Therapeutics (U.S.), Inc. | $21 | Food and Beverage | In-kind items and services | VALCHLOR Drug, ONCOLOGY | 2025 | |
| 2025-03-14 | GENZYME CORPORATION | $29 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-03-13 | SUN PHARMACEUTICAL INDUSTRIES INC. | $28 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-03-10 | Incyte Corporation | $63 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-03-09 | Novartis Pharmaceuticals Corporation | $32 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-02-28 | Galderma Laboratories, L.P. | $29 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-02-28 | KYOWA KIRIN, INC. | $23 | Education | In-kind items and services | POTELIGEO Drug, MONOCLONAL ANTIBODY | 2025 | |
| 2025-02-28 | KYOWA KIRIN, INC. | $22 | Food and Beverage | In-kind items and services | POTELIGEO Drug, MONOCLONAL ANTIBODY | 2025 | |
| 2025-02-26 | GlaxoSmithKline, LLC. | $17 | Food and Beverage | In-kind items and services | BENLYSTA Biological, IMMUNOLOGY | 2025 | |
| 2025-02-25 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-02-19 | Smith+Nephew, Inc. | $33 | Food and Beverage | In-kind items and services | OASIS Device, Extra Cellular Matrix | 2025 | |
| 2025-02-18 | Krystal Biotech Inc | $119 | Food and Beverage | In-kind items and services | VYJUVEK Drug, DERMATOLOGY | 2025 | |
| 2025-02-17 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-02-11 | UCB, Inc. | $27 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-02-07 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-02-07 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-02-06 | UCB, Inc. | $6,972 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-02-04 | Organon Llc | $17 | Food and Beverage | In-kind items and services | VTAMA Drug, Dermatology | 2025 | |
| 2025-01-30 | UCB, Inc. | $2,075 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-01-29 | Regeneron Healthcare Solutions, Inc. | $33 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-01-28 | Lilly USA, LLC | $22 | Food and Beverage | In-kind items and services | TALTZ Drug, Immunology | 2025 | |
| 2025-01-24 | UCB, Inc. | $133 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-01-23 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | COSENTYX Drug, Dermatology | 2025 | |
| 2025-01-18 | Amgen Inc. | $113 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 |
The latest 200 records of 803.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-11-14 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $3,509 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2025 |
| 2025-11-03 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $1,000 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2025 |
| 2025-09-24 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $6,308 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2025 |
| 2025-09-24 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $2,525 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2025 |
| 2025-09-05 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $1,660 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2025 |
| 2025-08-08 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $1,840 | A Multinational, Multicenter, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of SAR44465 | 2025 |
| 2025-08-08 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $791 | A Multinational, Multicenter, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of SAR44465 | 2025 |
| 2025-08-08 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $1,150 | A Multinational, Multicenter, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of SAR44465 | 2025 |
| 2025-08-06 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $3,084 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2025 |
| 2025-08-06 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $165 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2025 |
| 2025-08-06 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $99 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2025 |
| 2025-07-11 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $1,150 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2025 |
| 2025-07-02 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $36,709 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2025 |
| 2025-06-11 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $224 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2025 |
| 2025-06-11 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $217 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2025 |
| 2025-05-02 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $165 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2025 |
| 2025-05-02 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $30,794 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2025 |
| 2025-05-02 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $500 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2025 |
| 2025-04-02 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $133 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2025 |
| 2025-04-02 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $277 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2025 |
| 2025-03-26 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $1,750 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2025 |
| 2025-03-19 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $99 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2025 |
| 2025-03-19 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $3,388 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2025 |
| 2025-03-07 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $1,242 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2025 |
| 2025-01-22 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $5,644 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2025 |
| 2024-12-18 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $930 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2024 |
| 2024-11-08 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $257 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2024 |
| 2024-11-01 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $28,642 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2024 |
| 2024-11-01 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $6,500 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2024 |
| 2024-11-01 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $500 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2024 |
| 2024-11-01 | SANOFI US SERVICES INC. | Wayne Health Obgyn | $534 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2024 |
| 2024-09-20 | SANOFI US SERVICES INC. | WAYNE STATE UNIVERSITY | $6,500 | A Multinational, Multicenter, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of SAR44465 | 2024 |
| 2024-09-18 | SANOFI US SERVICES INC. | WAYNE STATE UNIVERSITY | $1,008 | A Multinational, Multicenter, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of SAR44465 | 2024 |
| 2024-09-11 | SANOFI US SERVICES INC. | WAYNE STATE UNIVERSITY | $1,008 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2024 |
| 2024-08-28 | SANOFI US SERVICES INC. | WAYNE STATE UNIVERSITY | $570 | A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR44 | 2024 |
| 2022-11-08 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $117 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2022 |
| 2022-11-08 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $367 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2022 |
| 2022-11-08 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $3,536 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2022 |
| 2022-09-01 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $1,500 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2022 |
| 2022-08-09 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $1,500 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2022 |
| 2022-08-04 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $990 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2022 |
| 2022-07-26 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $594 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2022 |
| 2022-07-12 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $660 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2022 |
| 2022-02-08 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $2,649 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2022 |
| 2021-11-23 | PFIZER INC. | WAYNE STATE UNIVERSITY | $25,190 | A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF066 | 2021 |
| 2021-10-07 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $642 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2021 |
| 2021-09-07 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $3,009 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2021 |
| 2021-08-06 | PFIZER INC. | WAYNE STATE UNIVERSITY | $792 | A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF066 | 2021 |
| 2021-07-09 | PFIZER INC. | WAYNE STATE UNIVERSITY | $7,042 | A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF066 | 2021 |
| 2021-04-01 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $660 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2021 |
| 2021-04-01 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $1,500 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2021 |
| 2021-04-01 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $990 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2021 |
| 2021-02-09 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $2,649 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2021 |
| 2021-02-09 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $407 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2021 |
| 2021-01-12 | PFIZER INC. | WAYNE STATE UNIVERSITY | $990 | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPI | 2021 |
| 2020-12-15 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $990 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2020 |
| 2020-12-15 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $660 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2020 |
| 2020-12-15 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $660 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2020 |
| 2020-12-15 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $300 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2020 |
| 2020-12-15 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $1,500 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2020 |
| 2020-12-08 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $1,000 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2020 |
| 2020-12-08 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $2,649 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2020 |
| 2020-10-17 | PFIZER INC. | WAYNE STATE UNIVERSITY | $20,605 | A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF066 | 2020 |
| 2020-09-03 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $2,184 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2020 |
| 2020-06-18 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $2,649 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2020 |
| 2020-06-17 | PFIZER INC. | WAYNE STATE UNIVERSITY | $6,596 | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 | 2020 |
| 2020-04-14 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $1,000 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2020 |
| 2020-03-26 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $660 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2020 |
| 2020-03-12 | PFIZER INC. | WAYNE STATE UNIVERSITY | $6,880 | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 | 2020 |
| 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Karmanos Cancer Hospital | $660 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2020 |
| 2020-02-26 | PFIZER INC. | WAYNE STATE UNIVERSITY | $390 | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 | 2020 |
| 2020-02-26 | PFIZER INC. | WAYNE STATE UNIVERSITY | $12,117 | AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOS | 2020 |
| 2020-02-25 | PFIZER INC. | WAYNE STATE UNIVERSITY | $70 | A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF066 | 2020 |
| 2020-02-04 | PFIZER INC. | WAYNE STATE UNIVERSITY | $7,896 | AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOS | 2020 |
| 2020-01-23 | PFIZER INC. | WAYNE STATE UNIVERSITY | $1,557 | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 | 2020 |
| 2019-12-19 | Regeneron Pharmaceuticals, Inc. | KARMANOS CANCER HOSPITAL | $106 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT | 2019 |
| 2019-12-04 | PFIZER INC. | WAYNE STATE UNIVERSITY | $5,115 | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 | 2019 |
| 2019-12-02 | Regeneron Pharmaceuticals, Inc. | KARMANOS CANCER HOSPITAL | $4,212 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT | 2019 |
| 2019-11-23 | PFIZER INC. | WAYNE STATE UNIVERSITY | $1,431 | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 | 2019 |
| 2019-11-14 | Regeneron Pharmaceuticals, Inc. | KARMANOS CANCER HOSPITAL | $2,649 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT | 2019 |
| 2019-11-05 | PFIZER INC. | WAYNE STATE UNIVERSITY | $1,431 | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 | 2019 |
| 2019-10-23 | PFIZER INC. | WAYNE STATE UNIVERSITY | $16,692 | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 | 2019 |
| 2019-10-04 | PFIZER INC. | WAYNE STATE UNIVERSITY | $1,890 | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 | 2019 |
| 2019-10-01 | Regeneron Pharmaceuticals, Inc. | KARMANOS CANCER HOSPITAL | $1,000 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT | 2019 |
| 2019-10-01 | Regeneron Pharmaceuticals, Inc. | KARMANOS CANCER HOSPITAL | $2,649 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT | 2019 |
| 2019-09-17 | Regeneron Pharmaceuticals, Inc. | KARMANOS CANCER HOSPITAL | $660 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT | 2019 |
| 2019-07-09 | PFIZER INC. | WAYNE STATE UNIVERSITY | $42 | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 | 2019 |
| 2019-07-09 | PFIZER INC. | WAYNE STATE UNIVERSITY | $756 | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 | 2019 |
| 2019-07-02 | Regeneron Pharmaceuticals, Inc. | KARMANOS CANCER HOSPITAL | $172 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT | 2019 |
| 2019-07-02 | Regeneron Pharmaceuticals, Inc. | KARMANOS CANCER HOSPITAL | $172 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT | 2019 |
| 2019-07-02 | Regeneron Pharmaceuticals, Inc. | KARMANOS CANCER HOSPITAL | $660 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT | 2019 |
| 2019-07-02 | Regeneron Pharmaceuticals, Inc. | KARMANOS CANCER HOSPITAL | $2,649 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT | 2019 |
| 2019-06-27 | PFIZER INC. | BEAUMONT HOSPITAL - DEARBORN | $70 | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 | 2019 |
| 2019-06-20 | Regeneron Pharmaceuticals, Inc. | KARMANOS CANCER HOSPITAL | $990 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT | 2019 |
| 2019-06-20 | Regeneron Pharmaceuticals, Inc. | KARMANOS CANCER HOSPITAL | $1,500 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT | 2019 |
| 2019-06-11 | Regeneron Pharmaceuticals, Inc. | KARMANOS CANCER HOSPITAL | $3,011 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT | 2019 |
| 2019-05-16 | Regeneron Pharmaceuticals, Inc. | KARMANOS CANCER HOSPITAL | $1,000 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT | 2019 |
| 2019-05-16 | Regeneron Pharmaceuticals, Inc. | KARMANOS CANCER HOSPITAL | $660 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT | 2019 |
| 2019-05-01 | Regeneron Pharmaceuticals, Inc. | KARMANOS CANCER HOSPITAL | $2,649 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT | 2019 |
| 2019-02-07 | Regeneron Pharmaceuticals, Inc. | KARMANOS CANCER HOSPITAL | $7,282 | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Dearborn, MI, county Wayne County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Dearborn, MI | County Wayne County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 107,423 | 1,772,259 | 10,077,761 |
| Population, 2020 census P1 | 109,976 | 1,793,561 | 10,077,331 |
| Median age B01002 | 33.3 | 37.9 | 40.2 |
| Under 18 B01001 | 28.7% | 23.6% | 21.2% |
| 65 and over B01001 | 13.7% | 16.6% | 18.6% |
| Households B11001 | 36,695 | 700,591 | 4,076,369 |
| Foreign born B05002 | 30.3% | 10.3% | 7.2% |
| Median household income B19013 | $65,324 | $60,539 | $72,875 |
| Median family income B19113 | $74,152 | $79,522 | $93,357 |
| Per capita income B19301 | $30,588 | $34,906 | $40,735 |
| Poverty rate B17001 | 24.3% | 20.8% | 13.2% |
| Unemployment rate B23025 | 6.6% | 8.7% | 5.7% |
| Civilian labor force B23025 | 45,028 | 828,838 | 5,018,449 |
| Mean commute (minutes) B08013 | 21.7 | 24.7 | 24.2 |
| Bachelor's degree or higher B15003 | 34.6% | 27.6% | 32.4% |
| Housing units B25001 | 39,394 | 801,083 | 4,622,236 |
| Owner-occupied B25003 | 68.4% | 64.8% | 73.2% |
| Renters B25003 | 31.6% | 35.2% | 26.8% |
| Median home value B25077 | $218,800 | $178,500 | $231,600 |
| Median gross rent B25064 | $1,327 | $1,132 | $1,129 |
| White, not Hispanic B03002 | 87.3% | 47.9% | 72.4% |
| Black B03002 | 3.6% | 36.6% | 13.1% |
| Hispanic or Latino B03002 | 2.7% | 6.9% | 5.9% |
| Asian B03002 | 1.8% | 3.7% | 3.4% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Dearborn, MI.
Comments